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Dissociation of the Hepatic Phenotype from HNF4
and HNF1a Expression
Gary A. Bulla1,2 and David M. Kraus1
Dediﬀerentiated cells have served as tools to understand the molecular consequences of the
loss of tissue-speciﬁc pathways. Here we report the characterization of one of these cell lines,
M29, which lacks the liver-enriched HNF4-HNF1a pathway, in order to determine if this
class of variant cell lines could provide additional information regarding requirements for
tissue-type expression. We report that although the liver-speciﬁc a1-antitrypsin (a1AT) gene
remains silent despite reactivation of the HNF4/HNF1a pathway in the M29 cells, the
frequency of activation of an integrated a1AT-APRT transgene is increased 1000-fold in
response to these transcription factors. The human a1AT locus (introduced via chromosome
transfer) also remained silent on these cells, despite HNF4 and HNF1a expression. Results
from cell fusion experiments suggest that the defect in the M29 cells is recessive. Results
suggest that the M29 cells contain a defect that represses liver gene expression despite the
presence of the HNF4/HNF1a pathway.
KEY WORDS: Hepatocyte nuclear factor1; hepatocyte nuclear factor 4; hepatoma;
alpha-1; antitrypsin; gene silencing.
INTRODUCTION
The role of chromatin remodeling in gene activation has only recently been appre-
ciated. Many studies have clariﬁed a role of modiﬁcation of histones (acetylation,
methylation and phosphorylation) and DNA (methylation) in regulation of chro-
matin [1]. Although much is understood with regard to activation of genes that are
already active (enhanced transcription), signiﬁcant questions still remain regarding
the mechanism of activation of previously silent genes in the genome (such as those
spacially and temporally activated during diﬀerentiation and development). Several
studies in a variety of tissue culture models have shown that the mere presence of
transcription factors alone is not suﬃcient to activate tissue-speciﬁc genes [2–8].
Hepatocyte nuclear factor-la (HNF1a) and –4 (HNF4) are components of a liver-
enriched transcriptional activation pathway. This pathway is considered to play an
important role in establishment and maintenance of the hepatic phenotype [9–13].
Both HNF4 and HNF1a function via binding to upstream DNA sequences of target
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genes. Loss of these factors in dediﬀerentiated hepatoma cells results in silencing of
expression of a large panel of liver-speciﬁc genes [14, 15]. Further evidence for the
importance of these factors in hepatic gene regulation comes from the identiﬁcation of
functionally important binding sites in promoters of a large number of liver genes [16].
Recently, Young and collaborators reported that HNF1a binds the promoters of over
200 liver-speciﬁc and pancreas-speciﬁc genes in vivo [13]. HNF4)/- mice die early in
embryogenesis, suggesting that HNF4 plays an essential role in early development
[17].More recently, HNF1a has been also shown to be functionally important in b-cell
development and in the transcription of b-cell–speciﬁc genes [9, 10, 13, 18–20]. Indeed,
mutations in both HNF1a andHNF4 genes have been shown to map to disease loci of
a rare subtype of type II diabetes called Maturity Onset Diabetes of the Young
(MODY) [21]. Genetic knock-out experiments of HNF1a in mouse models have
exhibited type II diabetes symptoms [20, 22].
Molecular details of HNF4/HNF1a pathway activation have been investigated
in several cell culture systems. HNF4 and HNF1a are members of a regulatory loop,
in which each member activates transcription of the other [23, 24]. Autoregulation of
HNF1a has also been reported [25, 26]. Interestingly, HNF4 expression precedes
HNF1a expression during mouse development [27, 28], suggesting that HNF4 is a
key player in initiating pathways leading to liver-speciﬁc gene expression.
Cultured hepatoma cell lines and their dedifferentiated derivatives have been
extensively used to determine mechanisms of gene repression and activation of liver –
speciﬁc genes. It is striking that predictions resulting from these cell culture models
conﬂict with results using transgenic knock-out mice. Speciﬁcally, it has been shown
that introduction of HNF4 and/or HNF1a into dedifferentiated hepatoma cells
generally rescues expression of the endogenous HNF4 and HNF1a genes as well as
downstream target liver-speciﬁc genes [24, 29–32].
Likewise, hepatoma X ﬁbroblast cell hybrids also show loss of liver expression
(including absence of HNF4 and HNF1a). However, introduction of these tran-
scription factors into the hybrids generally fails to restore liver-speciﬁc gene
expression [7, 8, 33], although HNF4 introduction was shown to rescue endogenous
HNF1a expression in such hybrids [8]. Unlike karyotypically complete whole cell
hybrids, Bailly et al. [32] showed that the introduction of either HNF4 or HNF1a in
cell hybrids with reduced chromosome content resulted in cross-activation of the
corresponding endogenous gene as well as other hepatic functions.
Taken together, results from both dedifferentiated hepatoma cell lines and from
hepatoma x ﬁbroblast hybrid cells suggest that HNF4 and HNF1a play a crucial role
in activation of liver gene expression. However, mice lacking HNF4 continue to
express HNF1a and HNF1a-deﬁcient mice continue to express HNF4 [28, 34].
Indeed, the expression of the majority of liver genes silenced in dediﬀerentiated cells
and cell hybrids are unaﬀected or are only mildly aﬀected by the absence of either
HNF4 or HNF1a in transgenic mice in liver [28, 34] or pancreatic cells [20].
To further analyze the link betweenHNF4 andHNF1a and liver gene expression,
we have reported the characterization of hepatoma -derived cell lines which were
selected for failure to drive a selectable APRT transgene under the control of the
human alpha)1 antitrypsin (a1AT) promoter (a promoter dependent on HNF4 and
HNF1a) [7, 35–37].Most of these hepatoma variant cell lines fail to express HNF4 and
HNF1a as well as most liver-speciﬁc genes, yet can be rescued by the introduction of
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HNF4and/orHNF1a transgenes [29, 31].However, certain hepatomavariant cell lines
could not be rescued by the introduction of HNF4 or HNF1a.
Here we characterize the M29 cell line, a hepatoma variant cell line which lacks
HNF4 and HNF1a, but in which the introduction of these factors fails to rescue
hepatic gene expression [29]. The M29 cells failed to express 7 of 8 liver-speciﬁc genes
tested, yet clones that survived selection against the a1AT-APRT transgene
expression show complete rescue of liver gene expression. We show that although
HNF4 rescues HNF1a expression, the endogenous a1AT gene remains silent. We
show that HNF4 and HNF1a are able to bind DNA and result in a 1000–fold
increase in the reversion frequency to APRT+. An introduced human a1AT locus
was also refractory to reactivation by HNF4 and HNF1a. These results suggest that
a repressor-like activity is present in the M29 cells that prevents HNF4 and HNF1a
from activating the endogenous a1AT promoter, but that the a1AT-APRT transgene
located in a context that located free from the observed repression. Possible rami-
ﬁcations of these results are discussed.
MATERIALS AND METHODS
Cell Lines and Conditions
All cell lines described are derived from the rat liver tumor line H4IIEC3. Fg14
cells are an adenine phosphoribosyltransferase-positive (APRT+), xanthine-guanine
phosphoribosyltransferase-positive (GPT+) cell line derived from the APRT) and
hypoxanthine-guanine phosphoribosyltransferase-negative (HPRT)) Fado–2 cells
by stable transfection of gpt and aprt transgenes driven by the human a1-antitrypisin
(a1AT) gene promoter (–640 to –2 bp) [35]. Dediﬀerentiated cells lines, including
M29 cells, were derived from the Fg14 cells by negative selection against both APRT
and GPT transgene gene expression using 20 lg/ml 2,6-diaminopurine (DAP) and
30 lg/ml 6-thioxanthine, respectively [35]. M29 cells have a reversion rate to
APRT+ of approximately 10)5. All cells were grown and expanded in 1:1 Ham’s
F)12-Dulbecco’s modiﬁed Eagle’s medium plus 5% fetal bovine serum (Gibco) and
penicillin plus streptomycin.
RNA Analysis
Cytoplasmic RNA was extracted from nearly conﬂuent cell monolayers as
previously described [31]. RNA (5 lg) was extracted by NP-40 lysis, size fractionated
on 1% agarose)2.2 M formaldehyde gels (Bulla et al., 1992), and transferred onto a
nylon ﬁlter. The ﬁlters were prehybridized and probed at 42C in 50% formamide,
5X SSPE (1X SSPE = 150 mM NaCl, 1 mM EDTA, 10 mM sodium phosphate,
pH 7.4), 1% SDS, 5 · Denhardt’s solution (1 · Denhardt’s = 0.02% Ficoll, 0.02%
polyvinyl pyrrolidone, 0.02% BSA) and 10 lg/ml each poly-A and poly-C (Phar-
macia). Filters were hybridized to speciﬁc DNA probes labeled with 32P-dCTP by the
random hexamer primer method [38] or an a1AT speciﬁc 540-nucleotide 32P-UTP-
labeled riboprobe from linearized pAT500.2 as previously described [7]. Probe was
added in the same hybridization solution, and the ﬁlters were incubated overnight at
42 or 65C (a1AT). Cloned DNA sequences from a-tubulin (Ka)1 [39]), aldolase B
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(pHL413 [40]), b-ﬁbrinogen and c-ﬁbrinogen [41], phosphoenolpyruvate carboxy-
kinase (pPCK)10, [42]), transferrin (plivS)6, [43]), argininosuccinate synthetase
(pASr) and argininosuccinate lyase (pALr)3) [44], albumin (pRSA57, [45] and rat
HNF1a (3.6 kb cDNA) were used. Probed ﬁlters were washed twice for 5 min each in
2 x SSC, 0.1% SDS at RT, then 30 min in 0.2 x SSC, 0.1% SDS at 52C, and exposed
to ﬁlm for 1–5 days. For the a1AT probe, ﬁlters were washed in identical conditions,
except that all solutions were at 65C.
To detect HNF4 expression, a 179 nt riboprobe [29] was used. Total cellular
RNA (10 lg) was incubated with 1 · 106 cpm of HNF4 riboprobe and incubated
overnight at 52C. The mixture was digested with RNase T1 +A, and protected
fragments were resolved on 8% denaturing polyacrylamide gels. The gels were dried
and exposed to ﬁlm for 1 to 5 days.
Microcell-Mediated Chromosome Transfer
Chromosome donor cell line HDm-5 is a mouse ﬁbroblast cell line containing
two copies of human chromosome 14 marked with a neomycin resistance gene [46].
HDm-5 cells were incubated in the presence of 10 lg/ml colcemid for 48 h to
micronucleate the cells. Cells were then trypsinized, replated onto plastic bullets and
enucleated by centrifugation in the presence of 10 lg/ml cytochalasin B, as previ-
ously described [47]. Cells were then centrifuged and resuspended in serum-free
medium and ﬁltered through 8- and 5-lm ﬁlters. Particles were then concentrated by
centrifugation, resuspended and added to a conﬂuent monolayer of M29 cells. The
cell mixture was then fused using polyethylene glycol for one min. Cells were rapidly
washed three times, then medium added. After 24 h, cells were split 1:20 into
selective medium containing 3 mM Ouabain plus 500 lg/ml G418. Individual mi-
crocell hybrids were picked and expanded after three weeks using cloning rings. As a
control, M29 cells alone were treated under identical conditions.
PCR Reactions
PCR was performed using 200 ng of genomic DNA template, 200 mM dNTPs,
1.5 mM magnesium, 100 ng each primer, and 1.2 U Taq polymerase using a
Thermolyne thermocycler in a volume of 20 ll. Samples were denatured at 94C for 5
min, followed by 35 cycles of 94C for 1 min, 58C for 45 s, and 72C for 60 s. Primer
sequences for human a1AT were used to screen for the presence of human chromo-
somes 14 as described by Theune et al. [48]. Ampliﬁcation products were resolved on
3% agarose gels containing ethidium bromide and photographed.
Induction of NF-jB
Cells were treated in serum-free 1:1 Ham’s F12:Dulbecco’s modiﬁed Eagle’s
medium containing a combination of the following: 1 lg/ml lipopolysaccharide
(LPS), 5 U/ml interleukin)1b (IL)1b), 100 U/ml interferon-c (IFG-c), and 50 ng/ml
tumor necrosis factor-a (TNF-a) Sigma-Aldrich) as previously described [49].
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Nuclear Extracts
Nuclear extracts were prepared according to the method of Schreiber et al. [50]
with modiﬁcations. Brieﬂy, cells were removed with a cell scraper, centrifuged for
3 min at 550 · g, supernatant was discarded, and the pellet was resuspended in 400 ll
of chilled buﬀer I (5 mM MgCl2, 5 mM b-glycerol phosphate, 0.2 mM EDTA (or
EGTA), 0.3 M sucrose, 1 mM DTT, 0.5 mM PMSF, 1 · protease inhibitor cocktail,
20 mM Tris-HCl, pH 7.8). The protease inhibitor cocktail is 6.0 ng/ml leupeptin,
0.1 lg/ml aprotinin, 40 lMbenzamidine, and 20 ng/ml antipain. NP-40 was added to
a concentration of 0.5% and the samples were incubated on ice for 1 min before being
spun for 3 min at 2,200 · g. The supernatant was discarded and the pellet resuspended
in 100 ll of chilled buﬀer II (5 mMMgCl2, 350 mMNaCl, 0.2 mMEDTA, 10 mM b-
glycerol phosphate, 25% glycerol, 0.5 mM DTT, 0.5 mM PMSF, protease inhibitor
cocktail, 10 mMTris-HCl, pH 7.8). Samples were incubated on ice for 15 minutes and
centrifuged for 15 minutes at 4C at 10,000 · g. The pellet was discarded and the
supernatant was transferred to a new tube and stored at )70C.
Electrophoretic Mobility Shift Assay (EMSA)
Ten lg of nuclear protein were added to 4 mM Hepes, 10 mM NaCl, 0.3 mM
MgCl2, 2% glycerol, 0.6–1.2 lg of poly-dIdC, and a 1 · protease inhibitor cocktail
described in the nuclear extract procedure. To this solution, 1 · 104 cpm of the
labeled oligonucleotide was added and incubated with the protein for 15–30 minutes
at 4C. The following DNA oligonucleotides were used in the binding assays:
HNF1a, CCTTGGTTAATATTCACC; HNF4, AGCAAACAGGGGCTAAGT-
CCACTGGCTG, NF-jB TCGAGGGCUGGGAUUCCCCATCTC, and Oct)1
GGGGGTAATTTGCATTTCTAAGGG. Dye was added and the samples were
subjected to polyacrylamide gel electrophoresis for 2–3 h at 7.5 V/cm in a non-
denaturing polyacrylamide gel with 1 · TBE buffer (0.45 M Tris base, 0.44 M boric
acid, and 0.01 M EDTA, pH 8.0). The gel was then placed on Whatman ﬁlter paper,
dried, and exposed to ﬁlm for 1–5 days.
RESULTS
We previously described a selection strategy (see Fig. 1) for the isolation of
several hepatoma variant cell lines that are speciﬁcally defective in their ability to
activate the HNF4-HNF1a pathway. Despite the fact that liver-speciﬁc gene
expression is rescued by the introduction of cloned HNF4 and/or HNF1a in many of
hepatoma variant cell lines such as H11 and M38 [29, 31], other cell lines (e.g. M29
and HS2) could not be rescued [29].
M29 cells, as well as a panel of sister clones derived by selection against
expression of the a1AT-APRT transgene, were screened for the expression of several
liver-speciﬁc genes. The M29 cells failed to express 7 of the 8 liver-speciﬁc genes
tested, including those expressing a1AT, b-, and c-ﬁbrinogen, phosphoenolpyruvate
carboxykinase, albumin, argininosuccinate lyase, aldolase B and transferrin
(Fig. 2a). Argininosuccinate synthetase was the exception, with low but detectable
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expression detected in the M29 cells compared to the Fg14 parental cells. Thus, the
M29 cells appear to fail to express the majority of liver-speciﬁc genes.
An HNF4 expression plasmid was introduced into the M29 cells together
with a plasmid encoding G418 resistance. Pooled G418r clones (>100 cells per
pool) were collected and expanded. RNA was then harvested and analyzed by
Northern analysis. As shown in Fig. 2b, HNF4 mRNA was absent in the M29
cells, but the introduction of an HNF4 expression plasmid produced readily
detectable levels of HNF4 mRNA. We next asked whether the HNF1a and a1AT
genes were activated in the HNF4 expressing M29 cells. In agreement with pre-
vious results [51], HNF4 expression restored HNF1a expression to hepatoma
levels (Fig. 2c, lane 5), but failed to activate a1AT expression. The introduction of
the vector alone containing the hygromycin B resistance gene into the M29 cells
had no eﬀect on expression of HNF1a or a1AT genes (lane 4). Importantly,
pooled clones that survived backselection in HAT (requiring the a1AT-APRT
transgene expression), resulted in full reactivation of HNF1a and a1AT expression
(see ‘‘M29B’’, lane 16).
These results were conﬁrmed using electrophoretic mobility shift assays
(EMSA). Cell extracts were incubated with radiolabeled oligomers speciﬁc
for HNF1a, HNF4, and Oct1 (Fig. 3). The Fg14 cells produced readily detectable
HNF1a (left panel) and HNF4 (middle panel) binding activities. The M29 cells lack
HNF1a or HNF4 protein binding (Fig. 3). The introduction of an HNF1a expres-
sion plasmid, but not the vector alone, resulted in detectable HNF1a protein binding
(left panel, lane 3), but no detectable HNF4 protein binding activity. In contrast, the
introduction of HNF4 into the M29 cells resulted in moderate levels of both HNF1a
and HNF4 binding activity, suggesting that the HNF1a gene is activated by HNF4a
expression. As expected, the M29 APRT+ backselectants showed robust HNF4 and
HNF1a protein binding activity. Oct1 probing was used to control for cell extract
quality (right panel). Although Oct1 levels are similar in each of the cell lines, we
noted that the M29 cells consistently over-express two low molecular weight pro-
teins. The identity of these proteins is unknown, but they do not appear to correlate
with expression of HNF4 or HNF1a.
Fado -2 M38, H11, M29, HS2
Hepatoma  Mutants
Fg14
   1. α1AT- aprt
   2. α1AT- gpt
Select against
gpt  and aprt
expression
HNF4
HNF1
1AT
+
+
+
HNF4
HNF1
_
_
_
1ATα α
Fig. 1. Derivation of hepatoma cell lines used in this study. Plasmids
pAT-aprt and pAT-gpt, containing the )640 to )2 bp a1AT promoter,
were introduced into Fado-2 hepatoma cells to generate the Fg14 cell
line, as described (35). Negative selection against both aprt and gpt
expression was used to generate the hepatoma variant cell lines (M29,
M60….). The hepatoma variant cells lack detectable expression of a1AT,
HNF4 and HNF1a genes.
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Fig. 2. HNF4 fails to rescue rat or human a1AT gene expression in M29 cells. RNA analysis of liver
gene expression in M29-family cells. (a) Five micrograms of cytoplasmic RNA from indicated cell
lines was size-fractionated on replicate formaldehyde gels and probed sequentially with indicated
liver-speciﬁc genes. M38, M60…. are sister clones of the M29 cells described in this article.
Fg14 = hepatoma parental cells. RAT1= ﬁbroblast cell line RNA included as a negative control. (b)
RNAse protection analysis was carried out using an HNF4 antisense riboprobe. RNA from pooled
M29 cells transfected with vector alone or vector + HNF4 expression plasmid were tested. A
hepatoma · ﬁbroblast hybrid cell line was included as a non-liver expressing control. (c) M29 cells
(lanes 3–5) or M29(14n) cells (lanes 6–8) were stably transfected with vector alone or an HNF4
expression vector. These cell lines as well as somatic cell hybrid fusions were tested for a1AT and
HNF1a expression. M29 · FRI (hepatoma) and M29(14n) · FRI cell hybrids are shown in lanes 10–
13. M29 cells were also fused with an a1AT-negative liver-derived cell line, Hepn (lanes 14–15).
Lastly, M29 backselectants (M29B, lane 16) were also tested. The ethidium bromide stained gel is
included to verify RNA integrity. FRI=neo-marked FTO2B rat hepatoma cell line; a1AT= a1-
antitrypsin; c-ﬁb = c-ﬁbrinogen; b-ﬁb= b-ﬁbrinogen; AldB = aldolase B; Asr= argininosuccinate
synthetase; Tf = transferrin; Alb = Albumin; AL = argininosuccinate lyase; PepCK = phospho-
enolpyruvate carboxykinase.
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Ectopic HNF4 and HNF1 Expression Dramatically Increases the Reversion Rate
to APRT+ in the M29 Cells
Because dedifferentiated cells were isolated based on the loss of their ability to
drive expression of the APRT gene, counterselection in HAT or AAT allows for the
isolation of GPT+ or APRT+ revertants, respectively. We tested the reversion rates
to APRT+ and GPT+ in the M29 cells in the absence and presence of ectopic HNF4
or HNF1a expression (Table 1). The reversion rate to APRT+ in the non-
transfected cells was similar in the presence of AAT or HAT, approximately 2–5 ·
10)5. Analysis of pooled transfectants containing the G418 resistance vector alone or
a HNF1a expression vector expressing a mutant form of HNF1a (designated SM,
which is unable to bind DNA [37]) was unchanged (at approximately 10)5). How-
ever, pooled clones expressing HNF4 or HNF1a increased reversion rates nearly
1000-fold, to approximately 1.5 · 10)2 APRT+, but did not signiﬁcantly change the
GPT+ reversion rate in HAT selection. Levels of a1AT and HNF1a RNAs in the
pooled M29 backselectants were at hepatoma levels (Fig. 2c, lane 16), suggesting
Fig. 3. Activation of endogenous HNF1a in hepatomaHNF1a-/HNF4- cells stably transfected with
HNF4. M29 cells stably transfected with HNF4 or HNF1a expression plasmids (or vector plasmid
alone) were analyzed by EMSA. Nuclear extracts were incubated with end-labeled oligonucleotides
speciﬁc for HNF4, HNF1a or Oct1. Protein complexes were resolved on 4% PAGE gels and exposed
to ﬁlm for 1–3 days. For HNF1a binding (left panel), cell extracts were ﬁrst incubated at 65C for
5 min to remove non-speciﬁc binding activity. Fg14 is the hepatoma parent of M29 cells. M29
backselectants (MB29cells) are pooled clones surviving AAT selection medium. Oct1 binding was
included to verify cell extract quality.
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that the backselectants fully activated both the a1AT-APRT transgenes and the
endogenous liver-speciﬁc genes. These results suggest that forced expression of
HNF4 or HNF1a is able to activate the integrated human a1AT promoter constructs,
but that the endogenous liver-speciﬁc genes are not activated to detectable levels.
The Human a1AT Locus is Silent Despite the Presence of the HNF4-HNF1a Pathway
The above results suggest that forced expression of HNF4 or HNF1a activates
the human a1AT promoter. However, as shown above, ectopic HNF4 and HNF1a
expression fails to activate the endogenous a1AT gene in the M29 cells. To determine
whether the inability to detect a1AT gene expression is due to defective a1AT loci or
differences between rat and human promoter DNA sequences, we introduced the
human a1AT locus into the M29 cells. Microcell-mediated chromosome transfer was
used to transfer a neo-marked human chromosome 14 from human HSF113 ﬁbro-
blast cells into the M29 cells. Individual microcell hybrids were tested for the pres-
ence of the human a1AT gene using PCR analysis with speciﬁc primers for the a1AT
locus. Results show that the expected size of DNA fragment was observed in several
of the microcell hybrids (called M29(14n)), but not detected in pooled clones from
M29 cell self fusions (Fig. 4). Therefore, the human a1AT locus was successfully
transferred into the M29 cells.
We next introduced an HNF4 expression plasmid plus a hygromycin B resis-
tance plasmid into the M29(14n) cells and pooled hygromycin Br clones were tested
for liver gene expression by Northern analysis. Human a1AT RNA was undetectable
in the pooled transfectants (Figure 2c, lanes 6–8). To verify that the riboprobe used
is able detect both human and rat a1AT RNA, human HepG2 hepatoblastoma cells
were included (Fig. 2c, lane 9). The probe readily detected the human a1AT tran-
script in the HepG2 cells. Thus, these results suggest that it is unlikely that the reason
that the HNF4-expressing M29 cells fail to express a1AT gene is due to a defective
a1AT locus or species-related diﬀerences in promoter DNA sequences.
The Defect in the M29 Cells is Recessive
We next asked whether the defect in the M29 cells was recessive. To do this, we
carried out cell fusion experiments. First, we fused the M29 cells with rat hepatoma
cells marked with the neo gene (FRI cells). Hybrid cells were selected in hygromycin
B + G418. Only hybrid cells were able to survive these selection conditions, as self-
Table 1. Introduction of HNF4 and HNF1a Expression Plasmids Increases APRT+ Reversion Rate
1000-fold in M29 Cells. 107 Cells were Plated in the Indicated Selective Medium and Surviving Clones
Counted at 3 Weeks using Trypan Blue Exclusion.
M29 cells HAT AAT
Non-transfected 5.2·10)5 2·10)5
Vector <2·10)5 <2·10)5
HNF1a <6·10)5 1.3·10)2
HNF1a(mutant) <4.3·10)6 <4.3·10)6
HNF4 <1.6·10)5 1.6·10)2
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Fig. 4. Introduction of human chromosome 14 into M29 cells.
Human HSF113 ﬁbroblast cells containing a neo-marked chro-
mosome 14 were micronucleated and chromosomes transferred into
the M29 cells. Individual neor clones were screened for human
a1AT sequences by PCR using human-speciﬁc primers predicted to
amplify a 344 bp fragment. Controls include DNA from human
HSF113 cells, M29 self-fusions, and no DNA included in the assay.
Fig. 5. NF-jB induction proﬁle is recessive in M29 cells. Cell extracts made from Fg14, M29, M38
and M29 XM38 hybrid cells exposed to 1lg/ml LPS for 0 to 5 h were analyzed by the electrophoretic
mobility shift assay (EMSA). Extracts were incubated with radiolabeled NF-jB and Oct1-speciﬁc
oligomers and subjected to 4% PAGE. Gels were exposed to ﬁlm for 3 days.
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fusion experiments did not yield any clones. Fusion of the M29 cells with the hep-
atoma cells resulted in wild-type levels of a1AT expression in pooled hybrid cells
(Fig. 2c, lane 13). Similar fusions were made using the M29(14n) cells, which express
the introduced human a1AT locus. Fusion of the M29(14n) cells with the FRI cells
resulted in wild-type levels of HNF1a and a1AT RNAs (Fig. 2c, lanes 10–12 and 13).
We next asked whether fusion of the M29 cells with a hepatoma cell line (designated
Hepn) that has been shown to lack a1AT expression would produce hybrids with
restored a1AT expression. Results from the M29 x Hepn show that the hybrid cells
fail to express a1AT or HNF1a (Fig. 2, lanes 14–15).
We further determined whether the M29 cells have a recessive defect by mon-
itoring NF-jB binding. In agreement with previously published results [52], M29
cells produced nearly undetectable NFjB binding activity upon lipopolysaccharide
(LPS) exposure, even after ﬁve h exposure (Fig. 5a). Similarly, the parental Fg14
cells showed minimal NFjB induction (Fig. 5a). Fusion of the M29 cells with an-
other hepatoma variant cell line, M38, which has a dramatic LPS-induced NF-jB
induction phenotype [52, 53], resulted in cell hybrids with an intermediate induction
phenotype (Fig. 5b) that remained through the 24 h time point. As described above,
the Oct 1 binding was included to verify extract quality. Thus, the cell fusion
experiments suggest that the M29 cells contain a recessive defect that can be com-
plemented by fusion with hepatoma cells.
DISCUSSION
In this report, we used a well-characterized model cell system to understand the
molecular consequences of loss of tissue speciﬁc gene expression. Silencing
of mammalian tissue-speciﬁc gene expression in ‘‘variant’’ cell lines are a well-
documented epigenetic phenomenon (reviewed in [14, 15]). However, the mecha-
nisms responsible for gene silencing in these cells are unknown. In some cases, simply
the introduction of silenced transcription factors is suﬃcient to restore the liver
phenotype (discussed below) while others are refractory to reactivation.
Here we show that the hepatoma variant cell line M29, which fails to express
several liver-speciﬁc genes, does not restore a1AT gene expression with the intro-
duction of HNF4 or HNF1a. The previously silent HNF1a gene, however, was
reactivated by HNF4. Surprisingly, forced HNF1a expression failed to rescue HNF4
expression. This is in contrast to other reported hepatoma-derived cell lines de-
scribed by us [29, 31] and others [30, 32] in which introduction of HNF4 or HNF1a
restored expression of the other. Although the reason for this discrepancy is unclear,
it is possible that the defects in the M29 cells are more profound, aﬀecting multiple
pathways involved in tissue-speciﬁc gene expression.
Despite the fact that HNF4 or HNF1a expression failed to activate downstream
genes, we found that the introduction of either of these transcription factors into the
M29 cells was able to increase the reversion frequency due to a selectable transgene
(a1AT-APRT) by 1000-fold (from 10)5 to 10)2). In contrast, the HPRT+ reversion
rate remained unchanged upon HNF4 or HNF1a induction. The reason for this
discrepancy in unclear, since the introduced a1AT-HPRT transgene contains the same
a1AT promoter sequences as the a1AT-APRT construct. It is possible that position
eﬀects are responsible for these diﬀerences, whereby the location of insertion could
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aﬀect the ability of the transgene to respond to the introduced transcription factors.
However, it would be diﬃcult to assess this possibility due to the fact that multiple
copies of both constructs are integrated into the parental Fg14 cell genome [29].
Notably, the resulting frequency of reversion to APRT+ was still low (10)2) in
the transfected cells. If only 1% of the cells have reactivated liver gene expression,
this could account for the inability to detect expression of the endogenous a1AT
gene. However, it was previously reported that other hepatoma variants that are
rescued by introduction of HNF4 or HNF1a also show increased reversion rates due
to HNF1a introduction, with the M38 cell line increasing from 10)6 to 10)1 and the
H11 cells from 10)3 to 10)1 [29, 31]. Alternatively, the ability of HNF4 and HNF1a
to activate the a1AT–APRT transgene without activation of the a1AT locus in the
M29 cells suggest the presence of target sequences outside of the promoter sequences
(640 bp) used in the a1AT-APRT construct that are targeted for repression. Species-
speciﬁc differences between human and rat a1AT promoter sequences do not explain
these results, as we also found that the introduced human a1AT locus contained in
the M29 cells also failed to respond to HNF4 or HNF1a.
Evidence for long range regulation of the a1AT gene has been reported.
Mardsen and Fournier [54] recently identiﬁed a region of DNA upstream of the
human a1AT promoter sequences used in this study that is required for HNF1a-
mediated modulation of chromatin in the a1AT locus. Indeed, regulation of the
a1AT locus may come under distal control sequences, since a 70 kb region of the
chromosome in which the a1AT locus as well as three other genes reside appear to be
coordinately controlled [55].
The results using M29 cells are in contrast to other cell similar lines studied in
which HNF4 or HNF1a rescues both a1AT-APRT transgene expression and a1AT
gene expression [29, 56]. In the latter cases, the introduction of human chromosome
12 from a human hepatoma cell line into a hepatoma variant cell line correlated with
restoration of HNF4, HNF1a, and a1AT gene expression [56].
The comparison of the M29 cells with other comparable cell lines is useful.
Weiss and colleagues have isolated and characterized a series of cell lines derived
from rat hepatoma cells which fail to express the liver genes, including HNF4 and
HNF1a [30, 33, 57]. Three classes of cells were described, each with distinct char-
acteristics with regard to liver expression rescue by the introduction of cloned HNF4
and /or HNF1a. Two cells lines derived from H4II cells, C5 and H5, were of par-
ticular interest. Introduction of HNF4 into the H5 cells resulted in activation of the
HNF1a gene, and vice versa. In addition, several downstream target liver genes were
also activated [24, 30]. The H5 cells were similar to cells derived in our laboratory
(H11 and M38 cells) using a selection strategy in which introduction of these
transacting factors rescued several liver-speciﬁc genes [29]. In contrast, the C5 cells
were refractory to activation by either HNF4 or HNF1a [58]. Neither endogenous
HNF4 nor HNF1a were rescued by the other in the C5 cells.
The third class of cells described by Weiss et al. were chromosomally reduced
hepatoma x ﬁbroblast hybrid cells in which the liver phenotype could be completely
rescued with the introduction of either HNF4 or HNF1a [58]. This in contrast to
karyotypically complete cell hybrids, which are refractory to activation by the
introduction of transacting factors with the exception that HNF4 rescued HNF1a
expression (but not downstream HNF1a-responsive genes) [8].
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The M29 cells have a phenotype similar to cells reported by Chaya et al [58], in
which a hepatoma derived cell line showed that liver gene expression appeared to be
uncoupled from expression of HNF4 and HNF1a. Speciﬁcally, liver gene expression
ceased despite the presence of HNF4 and HNF1a.
Mouse knockouts in the HNF4 or HNF1a have relatively unaffected RNA
levels of liver gene expression, including levels of HNF4 or HNF1a mRNA.
Therefore, it remains a paradox why dedifferentiated cell lines and reduced cell
hybrids show such a dramatic dependence on these transcription factors for target
gene expression.
Recent data using chromatin precipitation demonstrated that HNF1a and
HNF4 interacts with the promoters of 100s of liver-enriched genes in vivo. Weiss et al
also showed that certain hepatoma derived cell lines express downstream target genes
in the absence on HNF4 and HNF1a, much like the transgenic HNF4 and HNF1a
knock-out mice. It is unclear what accounts for these very distinct phenotypes.
In conclusion, M29 appears to be a cell line with an unusual phenotype. Liver
gene expression fails to be restored upon introduction of an HNF4 expression
plasmid, despite reactivation of the previously silent HNF1a gene. However, the
reversion rate to APRT+ is increased 1000-fold upon introduction of either HNF4
or HNF1a. The APRT+ backselectants fully activated a1AT expression. It is pos-
sible that DNA methylation and/or histone modiﬁcation (methylation, acetylation,
phosphorylation) may contribute to the silencing of hepatic gene expression in the
hepatoma variant cells. This possibility is currently being tested.
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